Tech Company Financing Transactions

Proteon Therapeutics Funding Round

Proteon Therapeutics closed a $45 million Series D funding round on 5/16/2014. Investors included Abingworth, Bessemer Venture Partners and Deerfield Capital.

Transaction Overview

Company Name
Proteon Therapeutics
Announced On
5/16/2014
Transaction Type
Venture Equity
Amount
$45,000,000
Round
Series D
Investors

Abingworth (Lead Investor) (Timothy Haines)

Bessemer Venture Partners (Felda Hardymon)

Deerfield Capital

Devon Park Bioventures

Intersouth Partners (James Rosen)

MPM Capital (Todd Foley)

Pharmstandard

Prism VentureWorks (Brendan O'Leary)

Skyline Ventures (John Freund)

TVM Capital (Hubert Birner)

Vectis Healthcare and Life Sciences Fund

Proceeds Purpose
Proceeds will be used to fully fund the first Phase 3 clinical study of PRT-201. Proteon's lead product, PRT-201, is a recombinant human elastase in development to prolong the patency and reduce the failure of hemodialysis vascular access in patients with chronic kidney disease (CKD).

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
200 West St.
Waltham, MA 02451
USA
Phone
(781) 890-0102
Website
www.proteontherapeutics.com
Email Address
[email protected]
Overview
Proteon Therapeutics (NASDAQ: PRTO) is a biopharmaceutical company developing PRT-201, a novel human recombinant protein that permanently dilates segments of blood vessels, blocks vasospasm, and reduces the formation of vascular scarring.
Profile
Proteon Therapeutics LinkedIn Company Profile
Social Media
Proteon Therapeutics Company Twitter Account
Company News
Proteon Therapeutics News
Facebook
Proteon Therapeutics on Facebook
YouTube
Proteon Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Timothy Noyes
  Timothy Noyes LinkedIn Profile  Timothy Noyes Twitter Account  Timothy Noyes News  Timothy Noyes on Facebook
Chief Financial Officer
George Eldridge
  George Eldridge LinkedIn Profile  George Eldridge Twitter Account  George Eldridge News  George Eldridge on Facebook
Chief Medical Officer
Steven Burke
  Steven Burke LinkedIn Profile  Steven Burke Twitter Account  Steven Burke News  Steven Burke on Facebook
VP - Bus. Development
Daniel Gottlieb
  Daniel Gottlieb LinkedIn Profile  Daniel Gottlieb Twitter Account  Daniel Gottlieb News  Daniel Gottlieb on Facebook
VP - General Counsel
Matthew Kowalsky
  Matthew Kowalsky LinkedIn Profile  Matthew Kowalsky Twitter Account  Matthew Kowalsky News  Matthew Kowalsky on Facebook
VP - Manufacturing
John Najim
  John Najim LinkedIn Profile  John Najim Twitter Account  John Najim News  John Najim on Facebook
VP - Marketing
Scott Toner
  Scott Toner LinkedIn Profile  Scott Toner Twitter Account  Scott Toner News  Scott Toner on Facebook
VP - R & D
Pamela Gustafson
  Pamela Gustafson LinkedIn Profile  Pamela Gustafson Twitter Account  Pamela Gustafson News  Pamela Gustafson on Facebook

 

 

Browse more venture capital transactions:

Prev: 5/16/2014: GoldRun venture capital transaction
Next: 5/16/2014: PeopleDoc venture capital transaction

 

Share this article

 

About Our Venture Capital Transactions Database

We do our best to report on funding rounds that are announced publicly. All VC database entries reported here come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.